A randomized phase II study of elotuzumab with lenalidomide and low-dose dexamethasone in patients with relapsed/refractory multiple myeloma.

被引：0
|
作者：
Moreau, Philippe
Richardson, Paul Gerard Guy
Jakubowiak, Andrzej J.
Jagannath, Sundar
Raab, Marc
Facon, Thierry
Vij, Ravi
Reece, Donna Ellen
White, Darrell
Benboubker, Lotfi
Zonder, Jeffrey A.
Rossi, Jean-Francois
Tsao, Claire
Parli, Teresa
Kroog, Glenn Scott
Singhal, Anil
Lonial, Sagar
机构：
[1] Univ Hosp, Dept Hematol, Nantes, France
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[4] Mt Sinai Med Ctr, New York, NY 10029 USA
[5] Univ Klinikum Heidelberg, Heidelberg, Germany
[6] Hop Claude Huriez, Lille, France
[7] Multiple Myeloma Res Consortium, Norwalk, CT USA
[8] Washington Univ, Sch Med, St Louis, MO USA
[9] Princess Margaret Hosp, Program Multiple Myeloma, Toronto, ON M4X 1K9, Canada
[10] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada
[11] Hop Bretonneau, CHU Tours, Tours, France
[12] Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA
[13] CHU Lapeyronie, Montpellier, France
[14] Abbott Biotherapeut, Redwood City, CA USA
[15] Bristol Myers Squibb Global Clin Research Oncol, Princeton, NJ USA
[16] Emory Univ, Winship Canc Ctr, Atlanta, GA 30322 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8020
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A RANDOMIZED PHASE 2 STUDY OF ELOTUZUMAB WITH LENALIDOMIDE AND LOW-DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Moreau, P.
    Richardson, P.
    Jakubowiak, A.
    Jagannath, S.
    Raab, M.
    Facon, T.
    Vij, R.
    Reece, D.
    White, D.
    Benboubker, L.
    Zonder, J.
    Rossi, J. F.
    Tsao, C.
    Parli, T.
    Kroog, G.
    Singhal, A.
    Lonial, S.
    [J]. HAEMATOLOGICA, 2012, 97 : 474 - 474
  • [2] Elotuzumab in combination with lenalidomide and low-dose dexamethasone in relapsed or refractory multiple myeloma: A phase I/II study
    Lonial, S.
    Vij, R.
    Harousseau, J.
    Facon, T.
    Moreau, P.
    Leleu, X.
    Westland, C.
    Singhal, A. K.
    Jagannath, S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [3] A Phase 2 Study of Elotuzumab in Combination with Lenalidomide and Low-Dose Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma
    Lonial, Sagar
    Jakubowiak, Andrzej J.
    Jagannath, Sundar
    Raab, Marc S.
    Facon, Thierry
    Vij, Ravi
    Moreau, Philippe
    Reece, Donna E.
    White, Darrell J.
    Benboubker, Lotfi
    Zonder, Jeffrey A.
    Rossi, Jean-Francois
    Tsao, Claire
    Parli, Teresa
    Kroog, Glenn
    Singhal, Anil K.
    Richardson, Paul G.
    [J]. BLOOD, 2011, 118 (21) : 141 - 142
  • [4] Elotuzumab in Combination With Lenalidomide and Low-Dose Dexamethasone in Relapsed or Refractory Multiple Myeloma
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Leleu, Xavier
    Tsao, L. Claire
    Westland, Christopher
    Singhal, Anil K.
    Jagannath, Sundar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (16) : 1953 - 1959
  • [5] Elotuzumab In Combination with Lenalidomide and Low-Dose Dexamethasone In Patients with Relapsed/Refractory Multiple Myeloma: Interim Results of a Phase 1 Study
    Lonial, Sagar
    Vij, Ravi
    Harousseau, Jean-Luc
    Facon, Thierry
    Moreau, Philippe
    Leleu, Xavier
    Mazumder, Amitabha
    Kaufman, Jonathan L.
    Westland, Christopher E.
    Tsao, Claire
    Singhal, Anil K.
    Jagannath, Sundar
    [J]. BLOOD, 2010, 116 (21) : 805 - 806
  • [6] ELOTUZUMAB IN COMBINATION WITH LENALIDOMIDE AND LOW DOSE DEXAMETHASONE IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE 1/2 STUDY
    Lonial, S.
    Vij, R.
    Harousseau, J. L.
    Facon, T.
    Moreau, P.
    Mazumder, A.
    Kaufman, J.
    Leleu, X.
    Tsao, C.
    Fry, J.
    Singhal, A.
    Jagganath, S.
    [J]. HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 157 - 158
  • [7] A randomized phase 2 study of pomalidomide/dexamethasone with or without elotuzumab in patients with relapsed/refractory multiple myeloma.
    San Miguel, Jesus
    Raab, Marc S.
    Goldschmidt, Hartmut
    Lonial, Sagar
    Richardson, Paul G.
    Shelat, Suresh
    Bleickardt, Eric W.
    Palumbo, Antonio
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [8] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Iida, Shinsuke
    Nagai, Hirokazu
    Kinoshita, Gen
    Miyoshi, Masafumi
    Robbins, Michael
    Pandya, Dimple
    Bleickardt, Eric
    Chou, Takaaki
    [J]. INTERNATIONAL JOURNAL OF HEMATOLOGY, 2017, 105 (03) : 326 - 334
  • [10] Elotuzumab with lenalidomide and dexamethasone for Japanese patients with relapsed/refractory multiple myeloma: phase 1 study
    Shinsuke Iida
    Hirokazu Nagai
    Gen Kinoshita
    Masafumi Miyoshi
    Michael Robbins
    Dimple Pandya
    Eric Bleickardt
    Takaaki Chou
    [J]. International Journal of Hematology, 2017, 105 : 326 - 334
12345